MedTrace Logo

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

NCT05208853 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-01-26

No results posted yet for this study

Summary

This is a single-center, open label, single dose study of anti CD30 CAR-T cells injection in treatment of patients with relapsed/refractory CD30+ lymphoma.

Conditions

  • Hodgkin Lymphoma
  • NK/T Cell Lymphoma
  • Peripheral T Cell Lymphoma, Unspecified
  • Angioimmunoblastic T-cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Mediastinal B-Cell Diffuse Large Cell Lymphoma
  • Gray Zone Lymphoma

Interventions

BIOLOGICAL

Anti CD30 CAR-T Cell Injection

After enrollment, subjects complete the apheresis, then complete the lymphodepletion, and then receive the dose escalation test: 1.5×10\^7 cells，1.5×10\^8 cells，5× 10\^8 cells. Drug: Fludarabine Fludarabine is used for lymphodepletion. Drug: Cyclophosphamide Cyclophosphamide is used for lymphodepletion

Sponsors & Collaborators

  • Shanghai First Song Therapeutics Co., Ltd

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Huang He, PhD · First Affiliated Hospital of Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2022-02-10
Completion
2022-02-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05208853 on ClinicalTrials.gov